SANUWAVE Health, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how SANUWAVE Health performed this year. My goal is to explain their progress and financial health clearly, without the confusing Wall Street jargon.

1. What does this company do?

SANUWAVE is a medical technology company focused on "regenerative medicine." They build devices that use non-thermal ultrasound to help the body heal chronic wounds, like diabetic foot ulcers. The device never touches the wound itself.

They use a "razor and blade" business model. They sell or lease their UltraMIST® system, then make steady money every time a clinic buys the sterile, single-use applicators needed for each treatment. As of December 31, 2025, they had 1,292 systems active in the field. These applicators create a predictable, high-profit revenue stream once a device is installed.

2. Financial performance: Growth vs. Growing Pains

The company grew significantly this year. Total revenue hit $44.1 million, a 35% increase over the $32.6 million reported in 2024. Gross profit margins stayed around 68%, showing that their applicators are very profitable compared to what they cost to make.

However, there is a major "growing pain." The company restated their financial results for 2024 and 2025 due to bookkeeping errors regarding sales taxes and revenue tracking for extended warranties. This adjustment lowered their previously reported profit by $1.2 million. They are currently installing new software and hiring senior accounting staff to address these internal control weaknesses.

3. Major wins and challenges

• The Win: Revenue is climbing, and UltraMIST is gaining popularity. The treatment is painless, fast, and covered by Medicare and Medicaid. The company successfully grew its number of active devices by 18% this year.
• The Challenge: The company is still rebuilding. They are spending heavily to grow their sales force to 65 representatives. They are not yet profitable, reporting a loss of $8.4 million this year. They are currently burning through about $650,000 per month and held $9.2 million in cash at the end of 2025.

4. Key risks

• Accounting Reliability: The recent restatement is a serious issue. Investors should be cautious until the company proves they have successfully implemented their new internal controls and completed a clean audit.
• Dilution: The company uses debt that can be turned into stock. They have $12 million in these notes outstanding. If converted, the company will issue millions of new shares, which reduces your ownership percentage.
• Regulatory Hurdles: The company relies on the FDA and insurance payments. Since 85% of their revenue comes from government programs like Medicare and Medicaid, any changes to how these programs pay for ultrasound wound care could significantly impact revenue.

5. Future outlook

The company is betting on moving wound care from hospitals into clinics and homes. They believe their portable technology fits this trend perfectly. Management aims to have 1,600 systems active by the end of 2026. They estimate this will drive revenue to $55 million, assuming clinics continue to use their applicators at the current rate.

Bottom Line for Investors: SANUWAVE is growing its footprint and revenue quickly, but the recent accounting restatement and ongoing cash burn are significant hurdles. When considering an investment, weigh the potential of their "razor and blade" model against the risks of share dilution and the company's heavy reliance on government-funded healthcare policy.